^
    Back
    Association details:
    Biomarker:PBRM1 mutation
    Cancer:Bladder Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

    Published date:
    10/20/2018
    Excerpt:
    In analyzing associations between single-gene alterations and pT0 response, PBRM1 was shown to be the only significant gene (seven of seven pT0; unadjusted P = .001; Data Supplement), 
    DOI:
    10.1200/JCO.18.01148
    Trial ID:
    PURE-01
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2018
    Title:

    Comprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC)

    Published date:
    10/01/2018
    Excerpt:
    Pembro is given 200mg q3w x3 cycles. Pathologic complete response (pT0) in ITT population is the primary endpoint (EP)….RB1 and PBRM1 GA were significantly associated with pT0 (p = 0.014 and p = 0.007).
    DOI:
    https://doi.org/10.1093/annonc/mdy283.075
    Trial ID:
    PURE-01